COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • June 10th, 2022 • G42 Investments AI Holdings RSC Ltd. • Pharmaceutical preparations • England and Wales
This Common Stock Purchase Agreement (this “Agreement”) is dated as of May 31, 2022 by and among vTv Therapeutics Inc., a Delaware corporation (the “Company”), G42 Investments AI Holding RSC Ltd, a private limited company incorporated in the Abu Dhabi Global Market with registered number 000003845 and with its registered address at Office 801, floor 8, Al Khatem Tower, Abu Dhabi Global Market Square, Al Maryah Island, Abu Dhabi, United Arab Emirates (the “Purchaser”) and, solely for purposes of Sections 5.3, 5.11 and Section 6, Group 42 Holding Limited, a private limited company incorporated in Abu Dhabi Global Market with registered number 000001430 and having its registered office at Office 801, Floor 8, Al Khatem Tower, ADGM, Al Maryah, Abu Dhabi, United Arab Emirates (“HoldCo”).
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)Joint Filing Agreement • June 10th, 2022 • G42 Investments AI Holdings RSC Ltd. • Pharmaceutical preparations
This agreement is made pursuant to Rule 13d-l(k)(1) under the Securities and Exchange Act of 1934, as amended (the “Act”) by and among the parties listed below, each referenced to herein as a “Joint Filer.” The Joint Filers agree that a statement of beneficial ownership as required by Sections 13(g) or 13(d) of the Act and the Rules thereunder may be filed on each of their behalf on Schedule 13G or Schedule 13D, as appropriate, and that said joint filing may thereafter be amended by further joint filings. The Joint Filers state that they each satisfy the requirements for making a joint filing under Rule 13d-1.
